A Groundbreaking Study on Heart Disease Management

In a significant leap forward for coronary artery disease (CAD) treatment, Heartflow, Inc. unveiled pivotal two-year findings from the remarkable FISH&CHIPS study. Recently published in the respected journal Nature Medicine, this extensive research covered over 90,000 patients and demonstrated a revolutionary diagnostic pathway that integrates Heartflow’s cutting-edge fractional flow reserve (FFRCT) technology with coronary computed tomography angiography (CCTA). This approach promises to not only enhance patient care but also streamline the healthcare process by reducing unnecessary tests.

Transforming Patient Care: Insights from the Study

Dr. Timothy Fairbairn, the principal investigator of the study at Liverpool Heart and Chest Hospital NHS Foundation Trust, shared the breakthrough’s implications: "The findings from FISH&CHIPS affirm that a national CCTA+FFRCT strategy can significantly transform patient journeys for those suspected of having CAD." This method sharply decreases the number of invasive procedures performed without justification, showcasing a 7% reduction in the need for invasive coronary angiography (ICA) and an impressive 16% drop in inappropriate procedures.

Enhanced Precision in Identifying Treatment Needs

One of the most compelling outcomes from the study is the enhanced ability to pinpoint patients in need of revascularization. The CCTA+FFRCT pathway led to identifying an additional appropriate intervention for every two unnecessary diagnostic catheterizations avoided. Furthermore, there was a notable 12% decrease in the requirement for follow-up non-invasive tests, marking a significant step towards more efficient patient care.

Setting the Standard Globally for Cardiac Diagnostics

"NHS's commitment to a CCTA-first approach has set a global benchmark for clinical efficacy," stated Campbell Rogers, M.D., Heartflow’s Chief Medical Officer. This innovative pathway is not just a local phenomenon; it has inspired clinical guidelines worldwide. By incorporating Heartflow’s FFRCT technology into the diagnostic process, healthcare systems can optimize testing and treatment strategies.

Heartflow: Pioneering Non-Invasive Cardiac Solutions

Heartflow stands as the singular provider of a non-invasive precision coronary care platform designed to manage CAD comprehensively. Utilizing the Heartflow One technology, a simple CCTA scan is transformed into a dynamic, personalized 3D heart model. This technology not only improves diagnostic accuracy but also empowers healthcare providers with granular insights into individual patient risks and treatment needs.

Join the Shift in Cardiac Care!

Heartflow is on a mission to revolutionize how coronary artery disease is understood and treated, striving to turn it from the leading cause of death into a manageable condition through proactive engagement. With over 1,400 institutions worldwide adopting their innovative methods, the future of cardiovascular care is brighter than ever. Discover more about how Heartflow is shaping this transformative journey at www.heartflow.com.